Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MannKind Corporation (MNKD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into MannKind’s operations as a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Among the key filings are Form 8-K current reports, which MannKind uses to describe material events. Recent 8-Ks document the completion of the acquisition of scPharmaceuticals, the terms of the related Contingent Value Rights Agreement, and the creation of additional borrowing capacity under a loan agreement to finance the transaction. Other 8-K filings discuss quarterly financial results, including revenue contributions from Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related royalties and collaborations, as well as changes in research and development and selling, general and administrative expenses.
Filings also cover MannKind’s clinical and regulatory decisions. For example, an 8-K filed in November 2025 describes the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility determination, and outlines the company’s intention to use those findings to guide ongoing development of MNKD-102, a dry powder formulation of clofazimine. Another 8-K details the first amendment to the global license and collaboration agreement with United Therapeutics, under which MannKind will formulate an additional Technosphere-based investigational product and is eligible for development milestones and royalties.
On this page, investors can review MannKind’s SEC-reported information on mergers and acquisitions, collaboration agreements, financing arrangements, and clinical program updates. Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand transaction structures, milestone obligations, and the potential impact on MannKind’s business. Users can also monitor newly posted 8-Ks and other SEC forms in near real time as they are released on EDGAR.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported first quarter 2026 total revenues of 90,171 (in thousands), up 15% from 78,354 (in thousands) a year earlier, driven mainly by Furoscix and higher royalties from Tyvaso DPI. Furoscix net sales were 15,493 (in thousands), while Afrezza net sales were 15,273 (in thousands).
Despite revenue growth, MannKind recorded a net loss of 16,619 (in thousands) versus net income of 13,158 (in thousands) in 2025 as cost of goods sold, research and development, and selling, general and administrative expenses all rose sharply, including amortization of acquired intangibles. The company highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, progress of MNKD-201 into Phase 2, an expanded ralinepag DPI collaboration with a 5,000 (in thousands) payment and up to 35,000 (in thousands) in potential milestones, and cash, cash equivalents and investments totaling 134 million as of March 31, 2026.
MannKind Corporation reported first quarter 2026 total revenues of 90,171 (in thousands), up 15% from 78,354 (in thousands) a year earlier, driven mainly by Furoscix and higher royalties from Tyvaso DPI. Furoscix net sales were 15,493 (in thousands), while Afrezza net sales were 15,273 (in thousands).
Despite revenue growth, MannKind recorded a net loss of 16,619 (in thousands) versus net income of 13,158 (in thousands) in 2025 as cost of goods sold, research and development, and selling, general and administrative expenses all rose sharply, including amortization of acquired intangibles. The company highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, progress of MNKD-201 into Phase 2, an expanded ralinepag DPI collaboration with a 5,000 (in thousands) payment and up to 35,000 (in thousands) in potential milestones, and cash, cash equivalents and investments totaling 134 million as of March 31, 2026.
MannKind Corp Chief Financial Officer Christopher B. Prentiss reported a routine tax-withholding share disposition. On April 22, 2026, 12,267 shares of common stock at $2.74 per share were withheld to cover taxes on Restricted Stock Units that vested from a grant dated May 15, 2024. After this, he directly held 338,924 shares, including 2,337 shares acquired through the Employee Stock Purchase Plan on December 31, 2025.
MannKind Corporation is asking stockholders to vote at its 2026 Annual Meeting, held virtually on May 20, 2026, on three key items: electing nine directors, approving executive pay on an advisory basis, and ratifying Deloitte & Touche LLP as auditor for 2026.
Stockholders of record on March 23, 2026, when 308,795,777 common shares were outstanding, may vote online before or during the meeting. The Board unanimously recommends voting FOR all director nominees, FOR the say‑on‑pay proposal, and FOR Deloitte’s ratification.
The proxy describes MannKind’s governance structure, including an independent chair, fully independent board committees, an anti‑corruption and insider‑trading policy, and director stock ownership guidelines. Non‑employee directors receive cash retainers plus annual restricted stock unit awards that generally vest immediately but are delivered after board service ends.
MannKind Corp — Amendment No. 4 to a Schedule 13G/A filed by The Vanguard Group reports beneficial ownership of 0 shares representing 0% of Common Stock. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that prompted disaggregated reporting by certain Vanguard subsidiaries. The report is signed by Ashley Grim on March 27, 2026, and states Vanguard entities have the right to receive dividends or proceeds for managed accounts, while no single outside person holds more than 5%.
MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.
The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.
MannKind Corp Chief Executive Officer Michael Castagna received new equity compensation awards. He was granted 796,000 performance-based restricted stock units, each representing the right to receive one share of common stock. The actual shares that vest on January 15, 2029 can range from 0% to 300% of this target, based on MannKind’s total shareholder return from April 1, 2026 to December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index.
He was also granted stock options for 782,000 shares of common stock at an exercise price of $2.4400 per share, expiring on March 23, 2036. These options vest 25% on March 23, 2027 and the remaining portion in equal quarterly installments over four years.
MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.
MannKind Corporation’s Chief Medical Officer, Ajay Ahuja, reported new equity awards. He received 221,000 performance-based restricted stock units, each representing a right to one share of common stock. These units vest on January 15, 2029, with the actual payout ranging from 0% to 300% of the target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted options on 217,000 shares of common stock at an exercise price of $2.44 per share. These options vest 25% on March 23, 2027, with the remaining 75% vesting in 1/16th increments quarterly, and expire on March 23, 2036. All positions are held directly and reflect compensation awards rather than market purchases or sales.